CTOs on the Move

Elysian Technology

www.elystech.com

 
Elysian Technology is an IT consulting firm that provides personalized solutions to meet the unique challenges of businesses. They focus on selecting applicable solutions rooted in proven Data Center fundamentals, with an eye to cloud and emerging solu...
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Greyson

Greyson Technologies is one of Florida`s fastest growing technology services companies, providing clients across the state with Advanced Network, Data Center and Unified Communications Solutions that help build their businesses. Our key business tenet is investing in our clients` success through personal engagement with our Florida-based team of trusted, certified professionals. We simplify technology adoption by understanding our clients` challenges and co-owing their delivery objectives. Greyson is a Cisco Gold Certified partner, and top-tier delivery partner with EMC, NetApp, VMware, Citrix, Microsoft and others enabling network, data, voice, and distribution services. The company is headquartered in Ft. Lauderdale, FL and maintains offices throughout the state.

Productspace Solutions

ProductSpace Solutions Inc is a company that provides Product Lifecycle Management (PLM) systems to connect people, processes, and technology in an enterprise to collaboratively develop products across the globe.

Woebot

Meet Woebot, your personal mental health ally that helps you get back to feeling like yourself. Backed by clinical research, powered by AI.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.